Tag: MM

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Onclive9

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Visit website
Immunotherapy Web Featured Images 81

Use of daratumumab for transplant-ineligible myeloma

During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.

Visit website
Patient Power

Patient Resource: Latest News on CAR T-Cell Therapy for Multiple Myeloma

  Jan 07 2021 Tagged CAR-T, MM

How can CAR T-cell therapy be used to treat multiple myeloma, and what is the latest in CAR T-cell research? Is it getting closer to being an approved treatment option? What are we learning from clinical trials? And finally, what should patients know?

Visit website
vjhemonic13

Comparing efficacy outcomes of ide-cel versus conventional care in R/R myeloma

Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discusses an analysis that compared efficacy outcomes seen in the MAMMOTH study, a retrospective observational study of conventional care regimens, and the KarMMA trial (NCT03361748) of the BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel), both in triple-class refractory multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 69

How is CT053 different from other BCMA-directed CAR T-cell therapies?

CT053 consists of autologous T cells genetically modified with a CAR incorporating a fully human BCMA-specific single-chain fragment variant, a 4-1BB intracellular domain, and a CD3 intracellular signaling region. The advantage over other CAR T-cell therapies is that it has a shorter manufacturing time, of 8–10 days, which allows a shorter interval between apheresis and infusion. Learn about the results of an ongoing phase I/II trial evaluating the safety and efficacy of CT053 in patients with relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 70

CARTITUDE-1 study: Are responses with cilta-cel deep and durable?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable? Madduri discusses the preliminary data from the CARTITUDE-1 study evaluating cilta-cel in patients with relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 79

Addition of daratumumab further improves the outcomes for patients with relapsed...

Positive trial results for the anti-CD38 mAb, isatuximab, plus pomalidomide and dexamethasone has led to European approval of this combination, but the regimen requires intravenous administration.

Visit website
Immunotherapy Web Featured Images 71

Patient Resource: Multiple Myeloma Roundtable - Immunotherapies & MRD Debate

Each year during the ASH Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Hear from three renowned experts and Patient Power co-founder Andrew Schorr as they discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.

Visit website
vjhemonic15

Future directions for multiple myeloma treatment

  Dec 17 2020 Tagged MM, CAR-T

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an overview of the evolving treatment paradigm for multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 61

Subanalysis of KarMMA study (idecabtagene vicleucel in MM) and updated results o...

In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.

Visit website